Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

NASDAQ:RAPT - Nasdaq - US75382E1091 - Common Stock - Currency: USD

1.13  +0.01 (+0.89%)

After market: 1.13 0 (0%)

Fundamental Rating

2

RAPT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While RAPT has a great health rating, there are worries on its profitability. RAPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RAPT had negative earnings in the past year.
In the past year RAPT has reported a negative cash flow from operations.
In the past 5 years RAPT always reported negative net income.
RAPT had a negative operating cash flow in each of the past 5 years.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

RAPT has a worse Return On Assets (-94.69%) than 73.08% of its industry peers.
RAPT's Return On Equity of -110.26% is in line compared to the rest of the industry. RAPT outperforms 43.01% of its industry peers.
Industry RankSector Rank
ROA -94.69%
ROE -110.26%
ROIC N/A
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RAPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

7

2. Health

2.1 Basic Checks

RAPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.34, we must say that RAPT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RAPT (-3.34) is comparable to the rest of the industry.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACC10.57%
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

RAPT has a Current Ratio of 8.14. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT's Current ratio of 8.14 is fine compared to the rest of the industry. RAPT outperforms 73.60% of its industry peers.
A Quick Ratio of 8.14 indicates that RAPT has no problem at all paying its short term obligations.
The Quick ratio of RAPT (8.14) is better than 73.78% of its industry peers.
Industry RankSector Rank
Current Ratio 8.14
Quick Ratio 8.14
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

RAPT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.30%.
EPS 1Y (TTM)-2.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RAPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.84% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.09%
EPS Next 2Y35.44%
EPS Next 3Y-10.02%
EPS Next 5Y12.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RAPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RAPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as RAPT's earnings are expected to decrease with -10.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.44%
EPS Next 3Y-10.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RAPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (3/7/2025, 8:00:01 PM)

After market: 1.13 0 (0%)

1.13

+0.01 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners82.04%
Inst Owner Change316.53%
Ins Owners0.43%
Ins Owner Change-683.59%
Market Cap149.17M
Analysts73.33
Price Target5.1 (351.33%)
Short Float %2.15%
Short Ratio0.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.75%
Min EPS beat(2)3.32%
Max EPS beat(2)4.17%
EPS beat(4)3
Avg EPS beat(4)2.36%
Min EPS beat(4)-6.73%
Max EPS beat(4)8.68%
EPS beat(8)6
Avg EPS beat(8)3.62%
EPS beat(12)10
Avg EPS beat(12)4.84%
EPS beat(16)12
Avg EPS beat(16)4.61%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)87.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)9.65%
EPS NY rev (3m)17.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.69%
ROE -110.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.14
Quick Ratio 8.14
Altman-Z -3.34
F-Score4
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)83.16%
Cap/Depr(5y)70.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
EPS Next Y74.09%
EPS Next 2Y35.44%
EPS Next 3Y-10.02%
EPS Next 5Y12.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.8%
EBIT Next 3Y8.84%
EBIT Next 5YN/A
FCF growth 1Y-61.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.95%
OCF growth 3YN/A
OCF growth 5YN/A